| |
Newsroom /
Health and Fitness
/
Healthcare
/
PRECISION THERAPEUTICS CEO PRESENTS AT J.P. MORGAN 28TH ANNUAL HEALTHCARE CONFERENCE
PRECISION THERAPEUTICS CEO PRESENTS AT J.P. MORGAN 28TH ANNUAL HEALTHCARE CONFERENCE
Precision Therapeutics, Inc. today announced that CEO Sean McDonald provided a company presentation at the J.P. Morgan 28th Annual Healthcare Conference, held at the Westin St. Francis Hotel in San Francisco, California, on Thursday, January 14, 2010.
Pittsburgh,
PA,
India
(prbd.net)
25/01/2010
"Precision Therapeutics, Inc. today announced that CEO Sean McDonald provided a company presentation at the J.P. Morgan 28th Annual Healthcare Conference, held at the Westin St. Francis Hotel in San Francisco, California, on Thursday, January 14, 2010"
Precision Therapeutics, Inc. today announced that CEO Sean McDonald provided a company presentation at the J.P. Morgan 28th Annual Healthcare Conference, held at the Westin St. Francis Hotel in San Francisco, California, on Thursday, January 14, 2010. The presentation included a discussion of the company’s marketed products, its strategy for growth, and other matters relating to its business.
Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult cancer therapy decisions.
Precision’s ChemFx®, a proprietary drug response marker, measures an individual patient’s tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician’s experience and provide valuable patient-specific information, as there is typically not a uniform response to standard cancer treatment or no clear choice for the next regimen.
For more information:
http://www.precisiontherapeutics.com
http://www.chemofx.com
###
About
Precision Therapeutics is a CLIA-certified diagnostics services company dedicated to providing physicians and patients with actionable clinical information to (http://www.chemofx.com/cancer-treatment/why-chemotherapy.html) personalize cancer treatments. Precision’s ChemoFx®, a proprietary live tumor cell-based platform, measures an individual patient’s tumor sensitivity and resistance to a range of therapeutic alternatives under consideration by a physician. This may help guide physicians when e
|